|
[1]
|
Dimopoulos, M.A., Kastritis, E. and Ghobrial, I.M. (2016) Waldenström’s Macroglobulinemia: A Clinical Perspective in the Era of Novel Therapeutics. Annals of Oncology, 27, 233-240. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Liu, J., Liu, W., Mi, L., Zeng, X., Cai, C., Ma, J., et al. (2019) Incidence and Mortality of Multiple Myeloma in China, 2006-2016: An Analysis of the Global Burden of Disease Study 2016. Journal of Hematology & Oncology, 12, Article No. 136. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Patir, P., Cerci, K. and Kurtoglu, E. (2025) Prognostic Evaluation of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Hematological Indices in Classic Hodgkin Lymphoma. International Journal of Laboratory Hematology, 47, 68-78. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., et al. (2003) Review of 1027 Patients with Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 78, 21-33. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Durie, B.G.M., Hoering, A., Abidi, M.H., Rajkumar, S.V., Epstein, J., Kahanic, S.P., et al. (2017) Bortezomib with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Patients with Newly Diagnosed Myeloma without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 389, 519-527. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Dimopoulos, M.A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., et al. (2016) Carfilzomib and Dexamethasone versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-Label, Multicentre Study. The Lancet Oncology, 17, 27-38. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Richardson, P.G., Kumar, S.K., Masszi, T., Grzasko, N., Bahlis, N.J., Hansson, M., et al. (2021) Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 39, 2430-2442. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Dimopoulos, M.A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E.A., et al. (2009) Long-Term Follow-Up on Overall Survival from the MM-009 and MM-010 Phase III Trials of Lenalidomide Plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Leukemia, 23, 2147-2152. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Richardson, P.G., Siegel, D.S., Vij, R., et al. (2014) Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma: A Randomized Phase 2 Study. Blood, 123, 3208-3209. [Google Scholar] [CrossRef]
|
|
[10]
|
Chari, A., Vogl, D.T., Gavriatopoulou, M., Nooka, A.K., Yee, A.J., Huff, C.A., et al. (2019) Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 381, 727-738. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Kumar, S.K., Harrison, S.J., Cavo, M., de la Rubia, J., Popat, R., Gasparetto, C., et al. (2020) Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 21, 1630-1642. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wudhikarn, K., Wills, B. and Lesokhin, A.M. (2020) Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action. Best Practice & Research Clinical Haematology, 33, Article 101143. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Timmers, M., Roex, G., Wang, Y., Campillo-Davo, D., Van Tendeloo, V.F.I., Chu, Y., et al. (2019) Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Frontiers in Immunology, 10, Article ID: 1613. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
van de Donk, N.W.C.J., Richardson, P.G. and Malavasi, F. (2018) CD38 Antibodies in Multiple Myeloma: Back to the Future. Blood, 131, 13-29. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Dimopoulos, M.A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N.J., Usmani, S.Z., et al. (2016) Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 375, 1319-1331. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T.M., Spicka, I., et al. (2018) Daratumumab Plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of Castor. Haematologica, 103, 2079-2087. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Chari, A., Suvannasankha, A., Fay, J.W., Arnulf, B., Kaufman, J.L., Ifthikharuddin, J.J., et al. (2017) Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood, 130, 974-981. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
An, G., Jiang, H., Acharya, C., Zhong, M.Y., Cai, T., Yang, G., et al. (2014) SAR 650984, a Therapeutic Anti-Cd38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma. Blood, 124, 4729-4729. [Google Scholar] [CrossRef]
|
|
[19]
|
Attal, M., Richardson, P.G., Rajkumar, S.V., San-Miguel, J., Beksac, M., Spicka, I., et al. (2019) Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 394, 2096-2107. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Dimopoulos, M.A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., et al. (2018) Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 379, 1811-1822. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Berdeja, J.G., Madduri, D., Usmani, S.Z., Jakubowiak, A., Agha, M., Cohen, A.D., et al. (2021) Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study. The Lancet, 398, 314-324. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Hu, Y., Hou, J., Jiang, Z. and Lin, Q. (2025) Mechanisms of Resistance to CAR-T Cell Therapy in Multiple Myeloma: Latest Updates from the 2024 ASH Annual Meeting. Experimental Hematology & Oncology, 14, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Neri, P., Leblay, N., Lee, H., Gulla, A., Bahlis, N.J. and Anderson, K.C. (2024) Just Scratching the Surface: Novel Treatment Approaches for Multiple Myeloma Targeting Cell Membrane Proteins. Nature Reviews Clinical Oncology, 21, 590-609. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Usmani, S.Z., Garfall, A.L., van de Donk, N.W.C.J., Nahi, H., San-Miguel, J.F., Oriol, A., et al. (2021) Teclistamab, a B-Cell Maturation Antigen × CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma (Majestec-1): A Multicentre, Open-Label, Single-Arm, Phase 1 Study. The Lancet, 398, 665-674. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Chari, A., Touzeau, C., Schinke, C., Minnema, M.C., Berdeja, J.G., Oriol, A., et al. (2025) Safety and Activity of Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma (Monumental-1): A Multicentre, Open-Label, Phase 1-2 Study. The Lancet Haematology, 12, e269-e281. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P.J., et al. (2024) Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 391, 393-407. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Dimopoulos, M.A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., et al. (2024) Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. New England Journal of Medicine, 391, 408-421. [Google Scholar] [CrossRef] [PubMed]
|